TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study

Detalles Bibliográficos
Autores principales: Lawitz, Eric, Loomba, Rohit, Denham, Douglas, Chung, Diana, Quirk, Erin, Lee, Lois, Marmon, Tonya, Kowdley, Kris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:
POSTER PRESENTATIONS: Saturday 25 June: NAFLD: Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252355/
http://dx.doi.org/10.1016/S0168-8278(22)01748-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252355/
http://dx.doi.org/10.1016/S0168-8278(22)01748-2

Ejemplares similares